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Background: Rates of contralateral risk-reducing mastectomy (CRRM) are rising, despite a decreasing global incidence
of contralateral breast cancer. Reasons for requesting this procedure are complex, and we have previously shown a
variable practice amongst breast and plastic surgeons in England. We propose a protocol, based on a published
systematic review, a national UK survey and the Manchester experience of CRRM.
Methods: We reviewed the literature for risk factors for contralateral breast cancer and have devised a 5-step
process that includes history taking, calculating contralateral breast cancer risk, cooling off period/counselling,
multi-disciplinary assessment and consent. Members of the multi-disciplinary team included the breast surgeon,
plastic surgeon and geneticist, who formulated guidelines.
Results: A simple formula to calculate the life-time risk of contralateral breast cancer has been devised. This allows
stratification of breast cancer patients into different risk-groups: low, above average, moderate and high risk.
Recommendations vary according to different risk groups.
Conclusion: These guidelines are a useful tool for clinicians counselling women requesting CRRM. Risk assessment
is mandatory in this group of patients, and our formula allows evidence-based recommendations to be made.
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The last decade has seen a marked increase in the num-
bers of women requesting contralateral risk-reducing
mastectomy (CRRM) following a diagnosis of unilateral
breast cancer [1]. This is despite a decreasing incidence
globally of contralateral breast cancer (CBC) as a result
of successful adjuvant therapies [2]. A contributing fac-
tor has been the introduction of genetic testing to rou-
tine clinical practice, but this only accounts for a small
proportion of patients requesting the surgery. In breast
cancer patients with a known BRCA1/BRCA2 mutation,
CRRM is associated with a 48–63 % [3, 4] survival ad-
vantage. Given that rates of contralateral breast cancer
in this group are up to 4× greater than non-mutation
carriers, a discussion of CRRM is easy to justify. For the
majority of women with no known mutation, there ap-
pears to be little if any survival advantage to CRRM [5].* Correspondence: naren_basu@hotmail.com
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article, unless otherwise stated.There is a wealth of literature on the appropriate man-
agement of women requesting bilateral risk-reducing
mastectomy (BRRM) because of family history or known
genetic mutation [5]. Interest in risk-reducing surgery
has significantly increased recently, particularly since ce-
lebrities disclosed their experience of risk-reducing
mastectomies. Existing guidelines on BRRM include the
updated 2013 NICE Guidelines on Familial Breast Cancer
in the UK [6]. Protocols exist for the counselling process
for these women before embarking on the surgery, with
the Manchester guidelines for BRRM being amongst the
first [7]. However, no such protocols or guidelines are in
place for women requesting CRRM after a diagnosis of
cancer. The purpose of this paper is to propose a plan of
management with regard to CRRM. Our protocol is
based on a previously published systematic review of
risk factors for contralateral breast cancer [8], a national
survey of UK practice [9] and the Manchester experi-
ence of CRRM [10]. This is in a similar manner and for
similar reasons to the published Manchester guidelines
[7] for BRRM.is distributed under the terms of the Creative Commons Attribution 4.0
ns.org/licenses/by/4.0), which permits unrestricted use, distribution, and
give appropriate credit to the original author(s) and the source, provide a
indicate if changes were made. The Creative Commons Public Domain
.org/publicdomain/zero/1.0/) applies to the data made available in this
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Assessment of the patient requesting CRRM
These guidelines have been formulated to aid clinicians
dealing with requests for CRRM. Where possible, a level
of evidence has been assigned from the designations set
by the Centre of Evidence-Based Medicine. There are
several steps in the process of preoperative assessment
and counselling that are clinically important before an
informed consent to CRRM can be given. These can be
summarised as follows:
Step 1 Taking a history
Step 2 Calculating the risk of contralateral breast cancer
Step 3 Cooling off period whenever possible
Step 4 Multi-disciplinary team (MDT) discussion
Step 5 Patient consent
Step 1: Taking a history
The first element of history taking is to determine the
reasons behind a patient’s request to discuss CRRM. For
the majority of women, the decision to request contra-
lateral surgery is based on factors other than inherited
genetic risk [11]. Women with breast cancer may have
complex, multi-factorial reasons for requesting CRRM,
and so the history should typically begin with open-ended
questions to let the patient discuss her reasoning, objec-
tives, hopes and fears. Objective assessment of this is chal-
lenging, with only a few reports in the literature [11].
Table 1 lists the main reasons patients request CRRM
[12] and is verified by our own study of clinical practice
in England [9]. Patients list fear of a second diagnosis,
fear of chemotherapy and anxiety about their children’s
future as the main drivers, followed by gene mutation
status and family history—whereas surgeons rank gene
mutation and family history as the main reasons to offer
CRRM [9].
The breast cancer patient requesting CRRM is different
to the patient considering BRRM. Although the latter may
have experience of a family member’s breast cancer jour-
ney, they would not have had the personal experience of
breast cancer, and their reasons for choosing risk-
reducing mastectomy may vary significantly [11, 13, 14].Table 1 Reasons patients request CRRM [9–12]
Reasons patients request CRRM
Gene mutation
Family history




Offered TRAM/DIEP—a “once only” optionFear of developing another breast cancer is a frequently
expressed concern, but not necessarily related to whether
or not this would influence life expectancy [15]. For some
women, fear of having repeated chemotherapy is their
main concern. For others, it is mistrust of annual mam-
mographic surveillance particularly if their first breast
cancer was mammographically occult, or if they have had
a stressful ‘recall’ following a surveillance mammogram.
Greater confidence in good outcomes following breast re-
construction may prompt a discussion of whether better
symmetry might be obtained by bilateral rather than uni-
lateral mastectomy, a factor that may also explain the ‘An-
gelina Jolie’ effect of increased interest in BRRM [16]. For
women whose primary motive is better long-term survival,
a simple explanation that CRRM will not achieve this in
those who do not carry a gene mutation may stop the dis-
cussion going further. However, women may have strongly
held motivations for CRRM quite independent of any ef-
fect on survival chances, and these need to be understood
and recorded.
The clinical history also needs to assess the index
breast cancer and highlight any potential poor prognostic
indicators. It may be useful to objectively assess this risk
using one of several validated predictive tools readily avail-
able. In addition, any co-morbidities should be identified
that would influence further surgery and in particular re-
constructive surgery. In step 5 of the process, a more de-
tailed discussion is required of their expectations around
breast reconstruction including a discussion of the risks
and benefits of the reconstructive options in their case.
Step 2: Calculating the risk of contralateral cancer
Women being considered for CRRM should have an ob-
jective assessment made of their risk of developing CBC,
as well as an explanation of whether CRRM would or
would not influence survival prospects. It is well docu-
mented that many women overestimate their personal risk
of CBC and the survival benefit of CRRM and at the same
time underestimate the adverse effects of the additional
surgery [15, 17]. A significant proportion of breast cancer
patients will undergo CRRM despite knowing there is no
survival advantage in non-mutation carriers [17] with only
a small proportion understanding the limited survival
benefit in non-mutation carriers [17].
CBC risk is multi-factorial as seen in Table 2. It is im-
portant to calculate an individualised lifetime risk of
CBC to stratify patients into different risk-groups, prior
to consent for CRRM. This will facilitate the counselling
process and provide a useful standard so that practices
throughout can be audited.
The risk of CBC in patients with known BRCA gene
mutations is approximately 2–3 % per annum, and likely
higher in TP53 mutation carriers [18]. The baseline risk of
CBC in patients with no family history is approximately
Table 2 Summary of risk factors for CBC and levels of evidence [8]
Family history—<45 years with a first-degree relative (RR 2.5)—<55 years
with first degree relative (RR 1.5)—first degree relative with bilateral
disease (RR 3.5)Level II evidence (Reiner AS JCO—2013) [18]
Gene mutation status—BRCA1/2 mutation (RR4) Level II evidence
(Metcalfe 2004 JCO; Evans 2013) [4, 25]
Chest radiotherapy for Hodgkin’s lymphoma—rate of CBC unknown
Young age at diagnosis—<30 years 0.5–1.3 % annual CBC rateLevel II
evidence (Nichols, Lacey JCO 2011) [2]
ER status—ER positive (reference point RR 1)—ER negative (RR 1.3) Level
II evidence [26]
Anti-endocrine treatment (risk reduction), tamoxifen 50 % Aromatase
inhibitor 70 % Level I evidence [27, 28]
DCIS—0.6 % annual CBC risk of DCIS and/or invasive carcinoma(RR
1.0)Level I evidence [21]
Lobular histology combined with family history (RR2.0)
Oophorectomy under 40 years (risk reduction) (RR0.5)
Early menopause <45 year (risk-reduction)—published as abstract [29]
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ciated with a 50–70 % risk reduction, with a greater reduc-
tion in risk from aromatase inhibitors [8]. These baseline
risks can be modified by certain factors listed in Table 2.
Patients diagnosed with unilateral breast cancer request-
ing CRRM and who have a strong family history should
ideally have formal assessment of risk and genetic testing
carried out by a clinical geneticist. In other cases, a useful
objective assessment of risk of CBC can be calculated as
follows.
Life expectancy at birth for women varies within the UK
(range 78.5 years—Glasgow to Purbeck 86.6 year—Source
ONS) [20], and we have used 80 years as the average life
expectancy. Thus, to obtain the number of years of CBC
risk, we can simply use the following calculation:
80years – patients age yearsð Þ
¼ Number of years of CBC risk:
We can then use the quoted annual incidence of CBC
at 0.5 % per year as a guide to the background risk for
CBC in women diagnosed with breast cancer. To obtain
a life-time risk based on this, we can use the following
calculation (this assumes good life expectancy from the
ipsilateral primary and typically would only apply to
stage 1 cancers):
Number of years of CBC risk  0:5 %
¼ Life−time risk of CBC
Once this value has been calculated, we can modify
the risk based on patient’s personal risk profile as follows:
 Estrogen receptor (ER)-positive disease and on
anti-endocrine treatment—multiply by 0.5 (50 % risk
reduction) Gene carriers—multiply by 4 (2 % annual incidence
of CBC)
 Oophorectomy under 40 years (surgical,
chemotherapy induced or natural)—multiply by 0.5
(50 % reduction)
 Family history—multiply by 2 (unpublished data
based on our own family history clinic)
Note: where numerous factors are being considered,
the multiplicative interaction of factors is not known.
For those patients with a known genetic mutation and a
family history, consider modifying risk based on gene
mutations (i.e. multiply by 4) only. Anti-endocrine treat-
ment in those who have had oophorectomy under the
age of 40 years, consider risk reduction by one factor
(i.e. multiply by 0.5) as there is no data to our knowledge
on whether the relationship is additive.
The quoted baseline annual incidence of CBC of 0.5 %
per annum is reduced in ER-positive tumours by 50 %
after 5 years of adjuvant tamoxifen but even more by an
aromatase inhibitor.
Unilateral ductal carcinoma in situ (DCIS) is associ-
ated with an increased risk of developing a contralateral
invasive cancer or DCIS. This annual risk is estimated at
0.6 % [21] and may be used in the above formula.
These calculations are of course only a guide, but they
are useful to stratify risk into clinically relevant risk categor-
ies such as the following:
Low risk
<10 % remaining life-time risk of CBC
Above average risk
10–20 % remaining life-time risk of CBC
Moderate risk
20–30 % remaining life-time risk of CBC
High risk
>30 % remaining life-time risk of CBC
The use of risk categories has proved invaluable in the
context of BRRM, and there are several validated tools
now to calculate breast cancer risk based on family history
and lifestyle factors for women without a cancer diagnosis
[22] (i.e. Manchester Score, Tyrer-Cuzick, BOADICEA).
At present, there are no validated tools to calculate CBC
risk in the context of CRRM. Our experience of using the
above method has been previously presented in abstract
form and is a useful clinical tool for validation in future
studies [10].
Step 3: Cooling off period whenever possible
The decision-making process around BRRM is charac-
terised by several months of pre- and post-test counsel-
ling. In contrast, women who request CRRM may do so
within a few hours or days from their diagnosis of breast
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following a diagnosis of breast cancer may impact on
the shared decision-making process by limiting the time
available for careful consideration of the pros and cons
of CRRM.
For the majority of patients, it is probably in their best
clinical interest to defer any decision about CRRM until
after their primary cancer treatment has been com-
pleted. This “cooling off period” minimises the risk that
they make a decision for CRRM as a knee-jerk reaction
at a time when they are emotionally vulnerable. There
are exceptions to this recommendation however. These
include the patient with a known BRCA mutation who
may have made a decision many months or years previ-
ously to undergo bilateral mastectomies for therapeutic
and risk-reducing reasons in the event of a cancer being
diagnosed. Non-mutation carriers in the high-risk group
defined in step 2, such as those with a significant family
history or previous mantle radiotherapy, may also decide
on CRRM as part of their primary treatment on diagno-
sis of a unilateral cancer and again may not benefit from
a cooling off period.
Overall, the majority of women are satisfied with their
decision of CRRM up to a decade following surgery [Ref.
Frost et al., JCO 2005]. However, it is not known
whether timing of this decision impacts on the level of
satisfaction. Where feasible, this step allows women to
carefully consider the various options available to them
in a non-time constrained manner. However, this is
not always possible as the need to treat the affected
side and possible reconstructive options will influence
the decision-making process and the speed at which
happens.
Patients considering an immediate transverse rectus
abdominus muscle/deep inferior epigastric artery perfor-
ator (TRAM/DIEP) flap reconstruction for their primary
therapeutic mastectomy are also an important possible
exception and are discussed further in step 5.
Step 4: MDT discussion
Given the complexity of the decision-making process, all
women considering CRRM should be assessed in a
multi-disciplinary setting—surprisingly, this is not uni-
versally practised in the UK [9]. The core members of
the team should include breast care nurse, breast sur-
geon, oncologist, radiologist and pathologist and where
possible, an oncoplastic-reconstructive surgeon familiar
with the various reconstructive options including free
TRAM/DIEP. For patients with a family history, discus-
sion with a clinical geneticist of their risk of CBC and
the possibility of genetic testing should be offered during
the patients cooling off period. Often, the breast care
nurse will have developed a close relationship with the
patient and is the patient’s advocate at the MDTmeeting. She should have the option of requesting add-
itional psychology assessment if she feels necessary, but
we would not regard this as mandatory. The patients’
reasons for requesting CRRM should be discussed at the
MDT in the light of her objective risk of CBC, influence
on survival chances, risks and benefits of the additional
surgery, and the alternative options around surveillance
and imaging. Additionally, it is useful to review the im-
aging, as some women may be particular challenging
to offering radiological surveillance on the contralat-
eral side.
The main benefit of a multi-disciplinary approach is
that requests for CRRM can be scrutinised across vari-
ous specialties and facilitate shared decision-decision
making [23]. A recent report showed that introduction
of this approach resulted in almost a third of requests
for CRRM being declined, mainly due to a low risk of
CBC in light of a high risk of systemic relapse. There is
good evidence across various specialties supporting this
form of collaborative working [24]. Our own approach
enables the MDT process to consider each request for
CRRM on an individual basis prior to making a
consensus-led decision with the option of patient-led
appeal for extenuating circumstances.
Step 5: Patient consent
Each of the steps above is part of the consent process,
commencing with a clear discussion of the benefits that
the patient hopes to achieve with CRRM, and a clear ex-
planation of the objective risk of CBC and whether or
not any survival advantage can be achieved. Particularly
for the non-gene carrier where no survival advantage ex-
ists, the conclusion that CRRM is appropriate and has
the support of the MDT meeting should be recorded in
the clinical notes. The next step is to explore the various
reconstruction options available to the patient if that is
what she wishes, combined with a clear explanation of
the limitations of such surgery, its risks and complica-
tions. Unrealistic expectations of a perfect outcome and
no postoperative complications should be addressed if
present. The final step is the signing of a formal consent
form, on which there is only sufficient space for the re-
cording of a brief summary of the risks and benefits; all
of these prior discussions should be recorded within the
clinical notes prior to the actual signing of the form.
A particularly challenging situation is the patient who
requests CRRM at the same time as her therapeutic
mastectomy as part of her primary treatment. This puts
the surgeon under time pressure to go through a com-
plex consent process. For patients in the high-risk group
defined in step 2, the situation may be fairly straightfor-
ward as often the patient will have had considered bilat-
eral mastectomy as her preferred option long before the
actual diagnosis. For patients undergoing primary neo-
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straightforward because a period of several months of
“cooling off” between those first discussions and the final
decision to proceed give the surgeon and his/her MDT
time to complete the above steps. For the patient requir-
ing a therapeutic mastectomy as her first treatment, and
who chooses an immediate TRAM/DIEP flap as her pre-
ferred reconstruction, the decision has to be made
within a few days, as otherwise the option of bilateral
symmetrical reconstruction is lost forever. In these cir-
cumstances, there may be no time to proceed to a for-
mal genetic assessment or to offer a cooling off period.
The opportunity for CRRM should probably not be de-
nied to the patient in those circumstances, as long as the
risks and benefits are clearly explained and approved by
the MDT, and recorded in the clinical notes.
Currently, there is not enough provision in the UK for
every MDT to have an oncoplastic surgeon who can
offer free TRAM/DIEP recon as a core member. Many
MDTs in the UK have to refer out with to an extended
MDT member (usually a plastic surgeon) which causes
time delays and lengthens the decision-making process
for patients and anxiety levels. Ideally, all MDTs should
include an oncoplastic surgeon familiar with the various
reconstructive options.
Women who are deemed not suitable for CRRM are
currently offered annual mammography surveillance for
5 years or up to the age of 50 years—whichever is
longer.
Discussion
The management of breast cancer patients requesting
CRRM is complex and best undertaken in a multi-
disciplinary setting. Several challenges exist for clinicians
in this setting. The first is their inability to calculate ac-
curately the individualised risk of CBC for each patient
given the numerous risk factors already described. We
have suggested a potential framework, but development
of a validated algorithm remains a high priority in re-
search in this area of study. The other challenge remains
managing the expectations of women for whom CRRM
offers no survival advantage and who form the vast ma-
jority of women requesting CRRM.
This protocol serves as a tool for clinicians involved in
this complex shared decision-making process with their
patients. The simple risk calculation that we have de-
scribed is based on a published systematic review of
known risk factors and provides a clinically useful
method of assigning patients to a variety of risk categor-
ies. It is hoped that this risk calculation will aid both pa-
tients and clinicians to jointly come to a decision
regarding CRRM following a clear explanation of the ob-
jective risks of CBC and the potential benefits, risks and
limitations of CRRM. We acknowledge that it is notpossible to be prescriptive in terms of who should be
allowed or refused CRRM.
The main limitations of this protocol are that recom-
mendations are based on a systematic review of known
risk factors which have not been assessed in a clinical
setting. As such, the estimates of contralateral breast
cancer risk need to be used with caution when multiple
factors are being considered given that there is a limited
evidence base to assess if this interaction is multiplica-
tive. This formula has been designed to act as a guide ra-
ther than a precise tool for the objective assessment of
risk. Efforts are underway to validate this protocol in a
large retrospective study. However, to our knowledge,
there are no established guidelines to aid the clinician to
objectively assess requests for CRRM. As such, this
protocol is the first to attempt to address this important
issue. We hope that in the interim, these guidelines and
the steps described within them help in reaching a
shared decision. This will ensure each request for CRRM
is judged based on its own merits.Ethical approval
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